首页> 外文期刊>International journal of urology: official journal of the Japanese Urological Association >Clinical outcome of 36 male patients with primary urethral carcinoma: a single center experience.
【24h】

Clinical outcome of 36 male patients with primary urethral carcinoma: a single center experience.

机译:36名男性原发性尿道癌患者的临床结局:单中心经验。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: Retrospective analysis of male urethral carcinoma to assess the best therapeutic approach to the management of this tumor. METHODS: A review of 36 cases of male urethral carcinoma diagnosed and treated at our center was performed. Clinical features, treatment modality and outcomes were analysed. RESULTS: The overall median survival time was 55.16 months. The 5-year overall and disease-free survival rate for the cohort was 49% and 23%, respectively. The 5-year survival is 67% for low-stage versus 33% for high-stage tumors and is significantly different (P = 0.001). The survival was 72% for tumors of the distal urethra versus 36% for tumors of the proximal, with a P-value of 0.02. CONCLUSION: The tumor location and clinicopathological stage were the most important predictors of the disease-free and overall survival. Multimodal approach is necessary for achieving local control especially for proximal and higher stage tumors.
机译:目的:回顾性分析男性尿道癌,以评估治疗该肿瘤的最佳治疗方法。方法:对我中心确诊并治疗的36例男性尿道癌病例进行回顾。临床特征,治疗方式和结果进行了分析。结果:总体中位生存时间为55.16个月。该人群的5年总生存率和无病生存率分别为49%和23%。低期肿瘤的5年生存率为67%,而高期肿瘤的5年生存率则为33%,差异显着(P = 0.001)。远端尿道肿瘤的生存率为72%,而近端尿道肿瘤的生存率为36%,P值为0.02。结论:肿瘤的位置和临床病理分期是无病生存和总体生存的最重要预测指标。多模式方法对于实现局部控制尤其是近端和晚期肿瘤是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号